Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites.

<h4>Background and aim</h4>The aim of this study was to assess the impact of proton pump inhibitor (PPI) intake on the development of spontaneous bacterial peritonitis (SBP) or other infections, as well as on mortality, in a thoroughly documented cohort of patients with cirrhosis and asc...

Full description

Bibliographic Details
Main Authors: Mattias Mandorfer, Simona Bota, Philipp Schwabl, Theresa Bucsics, Nikolaus Pfisterer, Christian Summereder, Michael Hagmann, Alexander Blacky, Arnulf Ferlitsch, Wolfgang Sieghart, Michael Trauner, Markus Peck-Radosavljevic, Thomas Reiberger
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0110503
_version_ 1831759584392380416
author Mattias Mandorfer
Simona Bota
Philipp Schwabl
Theresa Bucsics
Nikolaus Pfisterer
Christian Summereder
Michael Hagmann
Alexander Blacky
Arnulf Ferlitsch
Wolfgang Sieghart
Michael Trauner
Markus Peck-Radosavljevic
Thomas Reiberger
author_facet Mattias Mandorfer
Simona Bota
Philipp Schwabl
Theresa Bucsics
Nikolaus Pfisterer
Christian Summereder
Michael Hagmann
Alexander Blacky
Arnulf Ferlitsch
Wolfgang Sieghart
Michael Trauner
Markus Peck-Radosavljevic
Thomas Reiberger
author_sort Mattias Mandorfer
collection DOAJ
description <h4>Background and aim</h4>The aim of this study was to assess the impact of proton pump inhibitor (PPI) intake on the development of spontaneous bacterial peritonitis (SBP) or other infections, as well as on mortality, in a thoroughly documented cohort of patients with cirrhosis and ascites.<h4>Patients and methods</h4>We performed a retrospective analysis of follow-up data from 607 consecutive patients with cirrhosis undergoing their first paracentesis at a tertiary center. A binary logistic regression model investigating the association between PPI intake and SBP at the first paracentesis was calculated. Competing risk analyses and Cox models were used to investigate the effect of PPIs on the cumulative incidence of SBP or other infections and transplant-free survival, respectively. Adjustments were made for age, hepatocellular carcinoma, history of variceal bleeding, varices and model of end-stage liver disease score.<h4>Results</h4>Eighty-six percent of patients were receiving PPIs. After adjusting for potential confounding factors, PPI intake was neither associated with increased SBP prevalence at the first paracentesis (odds ratio (OR):1.11,95% confidence interval (95%CI):0.6-2.06; P = 0.731) nor cumulative incidence of SBP (subdistribution hazard ratio (SHR): 1.38; 95%CI:0.63-3.01; P = 0.42) and SBP or other infections (SHR:1.71; 95%CI:0.85-3.44; P = 0.13) during follow-up. Moreover, PPI intake had no impact on transplant-free survival in both the overall cohort (hazard ratio (HR):0.973,95%CI:0.719-1.317; P = 0.859) as well as in the subgroups of patients without SBP (HR:1.01,95%CI:0.72-1.42; P = 0.971) and without SBP or other infections at the first paracentesis (HR:0.944,95%CI:0.668-1.334; P = 0.742).<h4>Conclusions</h4>The proportion of cirrhotic patients with PPI intake was higher than in previous reports, suggesting that PPI indications were interpreted liberally. In our cohort with a particularly high prevalence of PPI intake, we observed no association between PPIs and SBP or other infections, as well as mortality. Thus, the severity of liver disease and other factors, rather than PPI treatment per se may predispose for infectious complications.
first_indexed 2024-12-22T01:10:10Z
format Article
id doaj.art-97d3282da7d140e2a715e87508c07b32
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-22T01:10:10Z
publishDate 2014-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-97d3282da7d140e2a715e87508c07b322022-12-21T18:43:59ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-01911e11050310.1371/journal.pone.0110503Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites.Mattias MandorferSimona BotaPhilipp SchwablTheresa BucsicsNikolaus PfistererChristian SummerederMichael HagmannAlexander BlackyArnulf FerlitschWolfgang SieghartMichael TraunerMarkus Peck-RadosavljevicThomas Reiberger<h4>Background and aim</h4>The aim of this study was to assess the impact of proton pump inhibitor (PPI) intake on the development of spontaneous bacterial peritonitis (SBP) or other infections, as well as on mortality, in a thoroughly documented cohort of patients with cirrhosis and ascites.<h4>Patients and methods</h4>We performed a retrospective analysis of follow-up data from 607 consecutive patients with cirrhosis undergoing their first paracentesis at a tertiary center. A binary logistic regression model investigating the association between PPI intake and SBP at the first paracentesis was calculated. Competing risk analyses and Cox models were used to investigate the effect of PPIs on the cumulative incidence of SBP or other infections and transplant-free survival, respectively. Adjustments were made for age, hepatocellular carcinoma, history of variceal bleeding, varices and model of end-stage liver disease score.<h4>Results</h4>Eighty-six percent of patients were receiving PPIs. After adjusting for potential confounding factors, PPI intake was neither associated with increased SBP prevalence at the first paracentesis (odds ratio (OR):1.11,95% confidence interval (95%CI):0.6-2.06; P = 0.731) nor cumulative incidence of SBP (subdistribution hazard ratio (SHR): 1.38; 95%CI:0.63-3.01; P = 0.42) and SBP or other infections (SHR:1.71; 95%CI:0.85-3.44; P = 0.13) during follow-up. Moreover, PPI intake had no impact on transplant-free survival in both the overall cohort (hazard ratio (HR):0.973,95%CI:0.719-1.317; P = 0.859) as well as in the subgroups of patients without SBP (HR:1.01,95%CI:0.72-1.42; P = 0.971) and without SBP or other infections at the first paracentesis (HR:0.944,95%CI:0.668-1.334; P = 0.742).<h4>Conclusions</h4>The proportion of cirrhotic patients with PPI intake was higher than in previous reports, suggesting that PPI indications were interpreted liberally. In our cohort with a particularly high prevalence of PPI intake, we observed no association between PPIs and SBP or other infections, as well as mortality. Thus, the severity of liver disease and other factors, rather than PPI treatment per se may predispose for infectious complications.https://doi.org/10.1371/journal.pone.0110503
spellingShingle Mattias Mandorfer
Simona Bota
Philipp Schwabl
Theresa Bucsics
Nikolaus Pfisterer
Christian Summereder
Michael Hagmann
Alexander Blacky
Arnulf Ferlitsch
Wolfgang Sieghart
Michael Trauner
Markus Peck-Radosavljevic
Thomas Reiberger
Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites.
PLoS ONE
title Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites.
title_full Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites.
title_fullStr Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites.
title_full_unstemmed Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites.
title_short Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites.
title_sort proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites
url https://doi.org/10.1371/journal.pone.0110503
work_keys_str_mv AT mattiasmandorfer protonpumpinhibitorintakeneitherpredisposestospontaneousbacterialperitonitisorotherinfectionsnorincreasesmortalityinpatientswithcirrhosisandascites
AT simonabota protonpumpinhibitorintakeneitherpredisposestospontaneousbacterialperitonitisorotherinfectionsnorincreasesmortalityinpatientswithcirrhosisandascites
AT philippschwabl protonpumpinhibitorintakeneitherpredisposestospontaneousbacterialperitonitisorotherinfectionsnorincreasesmortalityinpatientswithcirrhosisandascites
AT theresabucsics protonpumpinhibitorintakeneitherpredisposestospontaneousbacterialperitonitisorotherinfectionsnorincreasesmortalityinpatientswithcirrhosisandascites
AT nikolauspfisterer protonpumpinhibitorintakeneitherpredisposestospontaneousbacterialperitonitisorotherinfectionsnorincreasesmortalityinpatientswithcirrhosisandascites
AT christiansummereder protonpumpinhibitorintakeneitherpredisposestospontaneousbacterialperitonitisorotherinfectionsnorincreasesmortalityinpatientswithcirrhosisandascites
AT michaelhagmann protonpumpinhibitorintakeneitherpredisposestospontaneousbacterialperitonitisorotherinfectionsnorincreasesmortalityinpatientswithcirrhosisandascites
AT alexanderblacky protonpumpinhibitorintakeneitherpredisposestospontaneousbacterialperitonitisorotherinfectionsnorincreasesmortalityinpatientswithcirrhosisandascites
AT arnulfferlitsch protonpumpinhibitorintakeneitherpredisposestospontaneousbacterialperitonitisorotherinfectionsnorincreasesmortalityinpatientswithcirrhosisandascites
AT wolfgangsieghart protonpumpinhibitorintakeneitherpredisposestospontaneousbacterialperitonitisorotherinfectionsnorincreasesmortalityinpatientswithcirrhosisandascites
AT michaeltrauner protonpumpinhibitorintakeneitherpredisposestospontaneousbacterialperitonitisorotherinfectionsnorincreasesmortalityinpatientswithcirrhosisandascites
AT markuspeckradosavljevic protonpumpinhibitorintakeneitherpredisposestospontaneousbacterialperitonitisorotherinfectionsnorincreasesmortalityinpatientswithcirrhosisandascites
AT thomasreiberger protonpumpinhibitorintakeneitherpredisposestospontaneousbacterialperitonitisorotherinfectionsnorincreasesmortalityinpatientswithcirrhosisandascites